Potential Of Angiotensin-(1-7) In Covid-19 Treatment

Authors

Patricia Luna, Faculty of Medicine, Benemérita Universidad Autónoma de Puebla- Puebla, México.
María Fernanda Pérez, Faculty of Health Sciences, Grupo de Investigación Avanzada en Biomedicina, Universidad Libre Seccional Barranquilla, Barranquilla, Colombia.
Jairo Castellar, Faculty of Exact and Natural Sciences, Grupo de Investigación Avanzada en Biomedicina, Universidad Libre Barranquilla, Barranquilla, Colombia.
Aileen Chang, Department of Medicine, George Washington University, Washington DC., US.
Yuliet Montoya, Grupo de Dinámica Cardiovascular (GDC), Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana.
John Bustamante, Grupo de Dinámica Cardiovascular (GDC), Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, john.
Wendy Rosales Rada, Faculty of Exact and Natural Sciences, Grupo de Investigación Avanzada en Biomedicina, Universidad Libre Barranquilla, Barranquilla, Colombia.
Evelyn Mendoza-Torres, Faculty of Health Sciences, Grupo de Investigación Avanzada en Biomedicina, Universidad Libre Seccional Barranquilla, Barranquilla, Colombia.

Document Type

Journal Article

Publication Date

11-30-2022

Journal

Current protein & peptide science

DOI

10.2174/1389203724666221130140416

Keywords

Angiotensin; COVID-19; SARS-CoV-2; clinical trials.; renin; treatment

Abstract

The new coronavirus currently named SARS-CoV-2 was announced by the World Health Organization as the virus causing the COVID-19 pandemic. The pathogenesis of SARS-CoV-2 initiates upon contact of a structural spike protein with the angiotensin II-converting enzyme receptor, leading to the induction of inflammatory mechanisms and progression to severe disease in some cases. Currently, studies have emerged linking COVID-19 with angiotensin-(1-7), demonstrating the potential of angiotensin-(1-7)/Mas Receptor axis induction to control disease severity due to its anti-inflammatory, vasodilator, antioxidant, antiproliferative, anticoagulant, antiangiogenic and fibrosis inhibitory effects. The renin angiotensin-system peptide Angiotensin-(1-7) shows a high therapeutic potential for COVID-19 mainly because of its ability to counteract the adverse effects caused in various organs due to angiotensin II-converting enzyme blockade. In light of these factors, the use of convalescent plasma conjugated therapy and Ang (1-7) agonists for the treatment of COVID-19 patients could be recommended. The differential expression of ACE2 and the varied response to SARS-CoV-2 are thought to be connected. According to several investigations, ACE2 antibodies and pharmacological inhibitors might be used to prevent viral entry. Given its capacity to eliminate the virus while ensuring lung and cardiovascular protection by regulating the inflammatory response, angiotensin-(1-7) is expected to be a safe choice. However, more clinical evidence is required to clarify the therapeutic usage of this peptide. The aim of this review article is to present an update of scientific data and clinical trials on the therapeutic potential of angiotensin-(1-7) in patients with COVID-19.

APA Citation

Luna, Patricia; Fernanda Pérez, María; Castellar, Jairo; Chang, Aileen; Montoya, Yuliet; Bustamante, John; Rosales Rada, Wendy; and Mendoza-Torres, Evelyn, "Potential Of Angiotensin-(1-7) In Covid-19 Treatment" (2022). GW Authored Works. Paper 1875.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/1875

Department

Medicine